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Case report
Two cases of possible transmitted drug
resistant HIV virus: Likely HIV
superinfection and unmasking of
pre-existing resistance
Fabiola Martin1, John Lee2, Emma Thomson3, Nick Tarrant4,
Antony Hale5 and Charles J Lacey1
Summary
In the UK, patients undergo HIV viral load and genotype testing before they are prescribed highly active antiretroviral
therapy. The genotype test guides clinicians in prescribing highly active antiretroviral therapy with maximum efficacy
against the patient’s specific viral strain. HIV viral load escape under antiretroviral drug therapy, to which the virus was
thought to be genotypically susceptible, is commonly observed in patients with poor adherence. We observed early viral
escapes in two newly diagnosed patients, during antiretroviral treatment, with different sequences compared to their
original viral resistance test and who reported excellent adherence to and tolerance of their therapy. HIV superinfection
with a new viral strain was identified in a patient with multiple risk factors and co-infections with sexually transmitted
diseases. The second patient was a case of the emergence of primary resistant virus under drug pressure. Both
suppressed their virus promptly after treatment switch.
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Case 1
A 41-year-old, White British, homosexual man pre-
sented complaining of drenching night sweats and fati-
gue of recent onset. He reported unprotected oral and
anal intercourse with casual partners and had recently
been diagnosed with Hepatitis C virus (HCV). He gave
no travel history of note. He was diagnosed with and
treated for early, secondary syphilis. His HCV genotype
was 1a (HCV RNA: 3.87 104 copies/mL) and his HIV
serology testing was negative. Four weeks later, he pre-
sented with night sweats, anorexia and dysphagia.
Oesophageal candidiasis was suspected and treated
with fluconazole 50mg once daily for seven days. HIV-
1 antibodies were positive (HIV viral load [VL]: 10 mil-
lion copies/mL, Log10 >5.8, CD4 count: 263 106/L,
21%). Acute HIV sero-conversion syndrome was diag-
nosed. Sequencing of protease (PR) and first 234 amino
acids of the reverse transcriptase (RT) genes indicated a
fully antiretroviral susceptible HIV-1 subtype B strain
with minor PR and RT differences to the HIV reference
strain HXB2 (K20R, E35D, N37E, L63P; V8I, V90I,
I142T, S162D, I178M). HCV RNA was undetectable,
suggesting spontaneous clearance of the HCV. Sixteen
weeks later, despite initial recovery, the CD4 had
declined to 185 106/L (12%). The HIV-1 VL was
167,200 copies/mL (Log10 5.2). Abacavir, lamivudine
and nevirapine were commenced and the VL supressed
to 270 copies /mL (Log10 2.4) at 12 weeks. Four weeks
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later, the patient presented feeling unwell with night
sweats. On examination, he had right-sided inguinal
lymphadenopathy and enlarged liver and a palpable
spleen. A pale macular rash was visible on the trunk
and extremities. He was diagnosed with rectal
Neisseria gonorrhoeae and urethral Chlamydia tracho-
matis, his HCV RNA remained negative. However, the
HIV VL had risen to 14,900 copies/ml (Log10 4.2) des-
pite good reported adherence and tolerance. HIV geno-
typing revealed HIV-1 subtype B with multiple new
mutations: PR: K14R, R83K, RT: A98S, K101E,
M184I, G190A, T215D, I135T, D177E, I178L, V179I,
T200A, I202V, Q207K, R211K. This virus, showed
high-level resistance to lamivudine and nevirapine and
low-level resistance to abacavir. The sequences were
highly divergent exhibiting 45 nucleotide differences of
which 20 were non-synonymous including the four resis-
tance-associated mutations (Figure 1). Considering the
history of repeated unprotected sex and co-infections
with sexually transmitted diseases together with the
number of changes in non-resistance mutations HIV
superinfection was suspected. This was confirmed by
phylogenetic analysis. Highly active antiretroviral ther-
apy (HAART) was changed to abacavir, lamivudine,
zidovudine and boosted atazanavir. The HIV VL was
<50 copies/mL (log10 1.6) within three weeks. Fifteen
months later, routine tests revealed newly raised AST
(73IU/L) and bilirubin (89 mmol/L) levels and HCV
RNA levels of 2.6 106 copies/mL. The two HCV
strains were identical in the 135 base region of the 5’
NCR. Considering the previous HCV RNA negative
tests and ongoing unprotected sex, HCV reinfection
was thought to be more likely than reactivation.
Case 2
A 41-year-old,White British, homosexual man receiving
treatment for pneumocystis jiroveci pneumonia was
diagnosed with HIV. The virus was subtype B and
fully antiretroviral susceptible (VL 260,000 copies/mL,
log10 5.4, CD4 count 4 106/L, 2.5%). He was com-
menced on tenofovir, emtricitabine and efavirenz. He
improved clinically, but the CD4 count plateaued at
11 106/L, 2.6%) and the VL only decreased to 88,000
copies/mL (log10 4.9) at 4 weeks and stalled at 56,000
copies/mL (log10 4.7) at 12 weeks. He reported no side-
effects, no new sexual contacts and 100% adherence to
HAART. He gave no travel history of note. Resistance
testing revealed K65KR, M184V, K101E, Y181CY and
G190CS. Comparison of the two sequences revealed
only four out of 1007 sequences nucleotide changes
between baseline and the second test, excluding residues
exhibiting mixed bases, of which three resulted in amino
acid changes within known resistance foci at RT residues
101, 184 and 190. The fourth was a synonymous
nucleotide change. Based on the fact that the patient
denied lack of exposure, reported good adherence and
the commonly under drug pressure observed mutations,
this lack of sufficient VL response was thought to be due
to an unmasking of a primary minority species virus
under drug pressure, rather than HIV superinfection.
The patient’s treatment was switched to combivir, ralte-
gravir and boosted darunavir. Twenty-four weeks
later he was feeling well and his VL was 41 copies/mL
(log10 1.6) and his CD4 count 155 106/L, 17%.
Discussion
We report viral escape as a consequence of potential
transmitted drug resistance due to HIV-1 superinfec-
tion and the unmasking of a primary minority species
resistant virus under drug pressure. In both case, viral
drug resistance was discovered following an insufficient
immunological and virological response. Both patients
had received information on transmission and preven-
tion of sexually transmitted diseases as well as HIV
superinfection and adherence to and side-effects of anti-
retroviral medication. We routinely provide free
condoms and advise to refrain from sex during the
sero-conversion period.
Poor adherence, ineffective HAART, HIV super-
infection and unmasking of primary resistant mutants
are known to be associated with lack of sufficient viro-
logical response.1 The latter two are rare but should be
considered in patients with good adherence to HAART.
A detailed history and HIV VL measurement, genotype
and phylogenetic analysis, especially ultradeep pyrose-
quencing,2 are useful in distinguishing the cause of viral
escape. HIV superinfection with a different virus can be
acquired after primary seroconversion.3,4 It is associated
with early HIV infection5,6 and estimated to occur at a
rate of around 5 per 100 person-years.2 It may lead to
the acquisition of drug resistance,7 viral escape, may
necessitate treatment switch and be associated with dis-
ease progression.8 In our case, repeat genotyping
detected the distinctly different new virus and guided a
successful treatment switch. We believe that the
archived resistance in case 2 was 194V and 101E as
these were not present in mixtures and that 65R and
181C then rapidly emerged as indicated by these being
mixed with wild type. The residue at 190 was also mixed
but not with wild type, and we cannot be sure whether
one or both of these were archived or emerged in differ-
ent quasi-species. We were not able to conduct ultradeep
sequencing, since it is not yet validated at our routine
virology service. However, the high divergence in the
first case and the lack of divergence in the second case
make superinfection in the first case and the unmasking
of a previous resistant variant in the second case, the
most likely explanation (Figure 1).
2 International Journal of STD & AIDS 0(0)
 at Glasgow University Library on April 20, 2015std.sagepub.comDownloaded from 
XML Template (2015) [4.2.2015–3:22pm] [1–4]
//blrnas3.glyph.com/cenpro/ApplicationFiles/Journals/SAGE/3B2/STDJ/Vol00000/150011/APPFile/SG-STDJ150011.3d (STD) [PREPRINTER stage]
Random samples of treatment naı¨ve HIV-infected
subjects harboured 5%, 3% and 3% primary resistant
HIV strains to NNRTIs, NRTIs and PIs, respectively.9
In the absence of drug pressure, the mutated virus may
revert back to wild-type and not be detectable with
simple genotyping.10,11 The overall rate of loss of muta-
tions was reported to be 18 per 10 person-years follow-
up, with large variation in the loss of NRTI mutations
(M184V rapid, M41L & thymidine analogue mutations
[TAMs] stable) over time and a more rapid loss of
NNRTI and PI mutations compared to TAMs.12
Using these data, in our second case, the M184V
and Y181C may have been lost quicker than the
remaining three; however, they re-emerged under drug
pressure.
We support the current practice:13 advising patients
to avoid unprotected sex, measuring VL at baseline at
4, 8, 12 and 24 weeks, tailoring treatment to the viral
Figure 1. Molecular phylogenetic analysis by maximum likelihood method. Branches derived from Case 1 are shown in red while
those from Case 2 are shown in blue. Branches in black were derived from reference sequences obtained from the NCBI database.
The evolutionary history was inferred by using the maximum likelihood method based on the General Time Reversible model.14 The
tree with the highest log likelihood (7594. 0650) is shown. The percentage of trees in which the associated taxa clustered together is
shown next to the branches. Initial tree(s) for the heuristic search were obtained automatically by applying Neighbor-Join and BioNJ
algorithms to a matrix of pair-wise distances estimated using the maximum composite likelihood approach and then selecting the
topology with superior log likelihood value. A discrete Gamma distribution was used to model evolutionary rate differences among
sites (five categories [þG, parameter ¼ 0.2316]). The rate variation model allowed for some sites to be evolutionarily invariable ([þI],
51.4057% sites). The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. The analysis
involved 104 nucleotide sequences. Codon positions included were 1stþ2ndþ3rdþNon-coding. All positions with less than 95% site
coverage were eliminated. That is, fewer than 5% alignment gaps, missing data and ambiguous bases were allowed at any position.
There were a total of 1006 positions in the final dataset. Evolutionary analyses were conducted in MEGA6.15 Bootstrap values >70%
are illustrated on the tree (1000 bootstrap replicates). Final editing was carried out using Figtree v1.4.2.
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genotype, repeating genotype in viral escape and
switching treatment in response to the new genotype.
Consent
Both patients have consented for the cases to be
published.
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